BRPI0921154A2 - 'silenciamento gênico mediado por e coli de beta-catenina' - Google Patents

'silenciamento gênico mediado por e coli de beta-catenina'

Info

Publication number
BRPI0921154A2
BRPI0921154A2 BRPI0921154A BRPI0921154A BRPI0921154A2 BR PI0921154 A2 BRPI0921154 A2 BR PI0921154A2 BR PI0921154 A BRPI0921154 A BR PI0921154A BR PI0921154 A BRPI0921154 A BR PI0921154A BR PI0921154 A2 BRPI0921154 A2 BR PI0921154A2
Authority
BR
Brazil
Prior art keywords
catenin
coli
beta
gene silencing
mediated gene
Prior art date
Application number
BRPI0921154A
Other languages
English (en)
Inventor
Johannes Heinrich Fruehauf
Original Assignee
Marina Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marina Biotech Inc filed Critical Marina Biotech Inc
Publication of BRPI0921154A2 publication Critical patent/BRPI0921154A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/72—Expression systems using regulatory sequences derived from the lac-operon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0921154A 2008-11-14 2009-11-13 'silenciamento gênico mediado por e coli de beta-catenina' BRPI0921154A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11461008P 2008-11-14 2008-11-14
PCT/US2009/064409 WO2010057009A1 (en) 2008-11-14 2009-11-13 E. coli mediated gene silencing of beta-catenin

Publications (1)

Publication Number Publication Date
BRPI0921154A2 true BRPI0921154A2 (pt) 2016-11-01

Family

ID=41838047

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921154A BRPI0921154A2 (pt) 2008-11-14 2009-11-13 'silenciamento gênico mediado por e coli de beta-catenina'

Country Status (11)

Country Link
US (1) US20100189691A1 (pt)
EP (1) EP2356235A1 (pt)
JP (1) JP2012508582A (pt)
KR (1) KR20110095319A (pt)
CN (1) CN102317457A (pt)
AU (1) AU2009313930A1 (pt)
BR (1) BRPI0921154A2 (pt)
CA (1) CA2742763A1 (pt)
IL (1) IL212461A0 (pt)
WO (1) WO2010057009A1 (pt)
ZA (1) ZA201103628B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
KR101520383B1 (ko) 2012-08-02 2015-05-15 에이비온 주식회사 Ｈｐｖ 감염과 관련된 암의 치료용 조성물
EP2903653B1 (en) 2012-10-02 2020-07-08 Vaxiion Therapeutics, LLC Immunomodulatory minicells and methods of use
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US10987432B2 (en) 2013-09-05 2021-04-27 The University Of Hong Kong Therapeutic delivery and expression system, methods and uses thereof
US20160177296A1 (en) * 2014-01-23 2016-06-23 Colorado State University Research Foundation E. COLI MEDIATED siRNA SILENCING OF AVIAN INFLUENZA IN CHICKENS
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017024059A1 (en) 2015-08-04 2017-02-09 Vaxiion Therapeutics, Llc Ionizing irradiation sterilization of bacterial minicell-based biopharmaceuticals and methods of use
GB201519734D0 (en) * 2015-11-09 2015-12-23 Univ Swansea Cancer therapy
WO2018102397A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
AU2018250169B2 (en) * 2017-04-03 2024-06-20 Sivec Biotechnologies, Llc A transkingdom platform for therapeutic nucleic acid delivery
CA3069523A1 (en) * 2017-07-11 2019-01-17 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
KR102083478B1 (ko) 2017-12-28 2020-04-28 한양대학교 산학협력단 Chi3l1 억제제를 유효성분으로 하는 암의 폐 전이 예방 또는 치료용 약학 조성물
EP3820992A2 (en) 2018-07-11 2021-05-19 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
EP3844276A2 (en) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
WO2022117658A1 (en) * 2020-12-01 2022-06-09 Redbiotec Ag Bacterial delivery of gene silencing tools into eukaryotic cells
WO2022256519A1 (en) * 2021-06-02 2022-12-08 Sivec Biotechnologies Llc Bacterial delivery of antibodies, antibody derivatives, and polypeptides to eukaryotic cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2305785A1 (en) * 1997-10-07 1999-04-15 University Of Maryland Biotechnology Institute Method for introducing and expressing rna in animal cells
EP2270136A1 (en) * 2004-12-17 2011-01-05 Beth Israel Deaconess Medical Center Compositions for bacterial mediated gene silencing and methods of using same
US20080311081A1 (en) * 2007-06-15 2008-12-18 Johannes Fruehauf Bacteria mediated gene silencing

Also Published As

Publication number Publication date
AU2009313930A1 (en) 2011-06-23
WO2010057009A1 (en) 2010-05-20
JP2012508582A (ja) 2012-04-12
CA2742763A1 (en) 2010-05-20
EP2356235A1 (en) 2011-08-17
US20100189691A1 (en) 2010-07-29
ZA201103628B (en) 2012-09-26
IL212461A0 (en) 2011-06-30
KR20110095319A (ko) 2011-08-24
CN102317457A (zh) 2012-01-11

Similar Documents

Publication Publication Date Title
BRPI0921154A2 (pt) 'silenciamento gênico mediado por e coli de beta-catenina'
BRPI0718796A2 (pt) Nucleotídeo
EP1982167A4 (en) BIOSENSOR
CR10841A (es) Imidazotriazinas imidazopirimidinas inhibidores de cinasa
DK2449883T3 (da) Herbicidsammensætninger
EP2018416A4 (en) DISPOSABLE BIOREACTOR
EP2092892A4 (en) ULTRASOUND DEVICE
NO347644B1 (no) Polymorfer
DE602007004361D1 (de) Endoskopsystem
DK1984502T3 (da) Nukleinsyre
BRPI0720224A2 (pt) Arilpirazóis substituídos
DE502007005526D1 (de) Pipettiervorrichtung
BRPI0716449A2 (pt) disposiÇço de refrigeraÇço
FR2895920B1 (fr) Pipette multivolumes.
DK1998622T3 (da) Herbicidsammensætning
EP2017608A4 (en) Biosensor
EP2156167A4 (en) BIOCHIP
EP2011880A4 (en) Taurine-GEN
DE112007001748A5 (de) Kupplung
EP2041570A4 (en) CellSpotTM APPLICATIONS
DK2005182T3 (da) Kliniske korrelater
EP2017607A4 (en) BIOSENSOR
SE0701180L (sv) Räddningsflytväst
DE502007000117D1 (de) Zierblende
EP2214719A4 (en) Metallofullerene-DYE

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]